Drug Profile
Research programme: prostaglandin receptor agonists - AbbVie
Latest Information Update: 19 May 2020
Price :
$50
*
At a glance
- Originator Asterand plc
- Developer AbbVie
- Class Small molecules
- Mechanism of Action Prostaglandin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 06 Apr 2011 No development reported - Preclinical for Eye disorders in USA (unspecified route)
- 09 Sep 2008 Preclinical trials in Eye disorders in USA (unspecified route)